Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
about
Emerging therapies for breast cancerSafety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
P2860
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Sequence-Specific Pharmacokine ...... Carboplatin in Women's Cancer.
@ast
Sequence-Specific Pharmacokine ...... Carboplatin in Women's Cancer.
@en
type
label
Sequence-Specific Pharmacokine ...... Carboplatin in Women's Cancer.
@ast
Sequence-Specific Pharmacokine ...... Carboplatin in Women's Cancer.
@en
prefLabel
Sequence-Specific Pharmacokine ...... Carboplatin in Women's Cancer.
@ast
Sequence-Specific Pharmacokine ...... Carboplatin in Women's Cancer.
@en
P2093
P2860
P1476
Sequence-Specific Pharmacokine ...... Carboplatin in Women's Cancer
@en
P2093
Bernard Parker
Brigitte C Widemann
Christina M Annunziata
Cody J Peer
Elise C Kohn
Jung-Min Lee
Lauren Amable
Lori Minasian
Nicolas Gordon
P2860
P304
P356
10.1158/1078-0432.CCR-16-1546
P407
P577
2016-09-23T00:00:00Z